Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study - AuspiCiOus

Academic Medical Center0 个研究点目标入组 25 人开始时间: 2021年5月26日最近更新: 2021年11月3日

适应症

试验速览

暂无简介。

•- Male or female adult patients (> 18 years)
•- Primaire tumor or metastasis accessible for repeat fresh histological biopsies
•- dMMR identified by IHC of mismatch repair proteins MLH1, PMS2, MSH2, and MSH6
•- Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or oesophagus; patients with HER2 positive disease are eligble when treatment with trastuzumab is contraindicated. If histology cannot be obtained, cytology is acceptable to prove metastatic disease
•- Patients with metastatic or irresectable adenocarcinoma of the stomach or oesophagus not pre-treated with chemotherapy or radiotherapy for irresectable or metastatic disease. Palliative radiotherapy on the primary tumor or a metastatic lesion is allowed if other untreated lesions eligble for evaluation are present
•- Measurable disease as assessed by RECIST 1.1
•- ECOG (WHO) performace status 0-2
•- Patient has adequate hepatic, renal and hematological function
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•- Past or current malginancy other than entry diagnosis interfering with prognosis of metastatic esophagogastric cancer

发起方

Academic Medical Center